Litigation Details for Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited (D. Del. 2019)
✉ Email this page to a colleague
Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited (D. Del. 2019)
| Docket | ⤷ Try a Trial | Date Filed | 2019-10-24 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | Assigned To | Leonard Philip Stark | |
| Jury Demand | Referred To | ||
| Patents | 8,101,659; 8,796,331; 8,877,938; 9,388,134 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-01-06 | 14 | Answer to Complaint | United States Patent Nos. 8,101,659 (the “’659 patent”), 8,796,331 (the “’331 patent”), and 8,877,938…103 mg, prior to the expiration of U.S. Patents Nos. 8,101,659 (the Case 1:19-cv-02021-LPS Document…and every asserted claim of United States Patent No. 8,101,659 is invalid for failing to satisfy one or… and enforceable asserted claim of U.S. Patent No. 8,101,659. …entered that each claim of United States Patent Nos. 8,101,659, 8,796,331, and 8,877,938 is invalid; | External link to document |
| 2022-08-26 | 196 | ~Util - Set Hearings AND Order | validity of U.S. Patent Nos. 8,877,938 (the 938 patent) and 9,388,134 (the 134 patent) is scheduled for…validity of U.S. Patent Nos. 8,101,659 (the 659 patent) and 8,796,331 (the 331 patent) is scheduled for…2019 7 February 2024 1:19-cv-02021 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2023-07-21 | 245 | Judgment | certain terms in the claims of U.S. Patent No. 8,101,659 (“’659 patent”) in a Memorandum Opinion and Order…/VALSARTAN) ) MDL No. 20-2930-RGA PATENT LITIGATION ) …, and to the extent that claims 1-4 of the ’659 patent are valid, that the filing of its respective ANDA… ANDA infringed each of claims 1-4 of the ’659 patent”), and that the products described in its respective… would infringe each of claims 1-4 of the ’659 patent (MDL No. 20-2930-RGA, D.I. 526, 709, 710) (“Stipulations | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
